With healthcare change comes challenge, but change also creates opportunity. This year's keynote general session for the NAMCP Spring Managed Care Forum was presented by Jacques Sokolov, MD, chairman and CEO, SSB Solutions, Inc, in Orlando, Florida.
With healthcare change comes challenge, but change also creates opportunity. This year’s keynote general session for the NAMCP Spring Managed Care Forum was presented by Jacques Sokolov, MD, chairman and CEO, SSB Solutions, Inc, in Orlando, Florida. Dr Sokolov’s presentation, “Rapidly Changing Payer, Physician, and Hospital Value Based Product Landscape Realities,” provides several significant points.
Dr Sokolov said that clinical integrated organizations (CIOs), accountable care organizations (ACOs), and super CIOs are pivotal to the evolution of value-based products. This is due to the need for a shift from the traditional fee-for-service to a fee-for-value, including shared savings and bundles. “Shared savings” are for population health (eg, Medicare Shared Savings Program, ACOs), and “bundled payments” are for episodes of care (eg, surgical or procedure based care). According to Dr Sokolov, 90% of revenue today is fee-for-service, whereas within 5 years, it may transition to a 50/50 revenue share with fee-for-value. Value-based payment, including bundles and shared savings, will come together for chronic and acute care clinical model optimization.
Dr Sokolov stressed that value-based products and the ability to deliver those products must be on the provider and physician agendas. In fact, physician leadership and engagement is essential to CIO success. He said CIO value-based contracts allow for revenue streams above and beyond traditional delivery systems. Additionally, CIOs are designed to meet the clinical and business needs of physicians, hospitals, and payers. As a learning organization, they’re “more nimble than it’s less advanced provider competitors (eg, non-integrated hospitals) and most traditional health plans.”
CIOs are not an end point; rather Dr Sokolov argues that they are a stepping stone to more sophisticated care management. Value-based care evolution needs to be addressed, or payers and physicians may fall behind in the changing healthcare market. The bottom line, Dr Sokolov says, is that profound changes are ahead for all healthcare organizations.
Discussing Sexuality, Mental Health With AYA Patients Amid the Hematological Treatment Journey
June 14th 2025Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Hematology in Space: Understanding How Blood Behaves Differently in Orbit
June 14th 2025Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further research is needed as commercial spaceflights are poised to grow in popularity.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More